Abstract:Abstract Aerobic glycolysis plays a pivotal role in the progression of tumors. Previously, a glycolysis‐associated prognostic model in CRC was constructed and the glycolysis‐related gene SPAG4 was discovered to be upregulated in CRC and was correlated with adverse prognosis. To date, however, no study has elucidated the specific role of SPAG4 in the development of CRC. In our study, CRC cells were transfected with si‐SPAG4 or OE‐SPAG4 to evaluate the influence of SPAG4 silencing or overexpression on CRC cell malignant behaviors. CRC cell proliferation and metastasis were detected via CCK‐8, colony formation, and Transwell assays. The oxygen consumption rate and extracellular acidification rate of CRC cells were determined by using an XF24 extracellular flux analyzer. The expression of SPAG4, key mitochondrial markers (NDUFA1, SDHB, ATP5A, and PGC‐1α), key enzymes involved in glycolysis (GLUT1, HK2, LDHA, PKM2, and PFK1), and PI3K/Akt pathway‐molecules and downstream transcription factor HIF‐1α was assessed by RT‐qPCR and western blot analysis. SPAG4 expression in CRC and normal tissue samples was tested through immunohistochemical staining. Finally, SPAG4‐overexpressed CRC cells were treated with LY294002 to validate the inhibition of PI3K/Akt pathway on CRC cell malignant phenotypes. Our results showed that SPAG4 was upregulated in CRC cells and tissues, and high expression SPAG4 predicted shorter overall survival time. SPAG4 knockdown inhibited while SPAG4 overexpression enhanced CRC cell proliferation, migration, invasion, mitochondrial respiration, and aerobic glycolysis. Overexpressing SPAG4 elevated p‐PI3K, p‐Akt, p‐mTOR, and HIF‐1α protein levels, which were restored after LY294002 treatment. Furthermore, LY294002 abolished the promotion of SPAG4 overexpression on CRC malignant phenotypes. Collectively, SPAG4 plays an oncogenic role in CRC by promoting mitochondrial respiration and aerobic glycolysis through activating the PI3K/Akt signaling. These findings suggest that inhibition of SPAG4‐mediated glucose metabolism may represent a potential strategy for the clinical treatment of CRC.

Therapeutic targeting of SPIB / SPI1 ‐facilitated interplay of cancer cells and neutrophils inhibits aerobic glycolysis and cancer progression

IC261, a Specific Inhibitor of CK1δ/ε, Promotes Aerobic Glycolysis Through P53-Dependent Mechanisms in Colon Cancer

Targeting MYC-enhanced Glycolysis for the Treatment of Small Cell Lung Cancer

SPI1 is a prognostic biomarker of immune infiltration and immunotherapy efficacy in clear cell renal cell carcinoma

Secreted Phosphoprotein 1 As a Potential Prognostic and Immunotherapy Biomarker in Multiple Human Cancers

SIPA1 Enhances Aerobic Glycolysis Through HIF-2α Pathway to Promote Breast Cancer Metastasis

Glycolytic neutrophils accrued in the spleen compromise anti-tumour T cell immunity in breast cancer

Metabolic regulation of cancer cell side population by glucose through activation of the Akt pathway

SHP-1 inhibition targets leukaemia stem cells to restore immunosurveillance and enhance chemosensitivity by metabolic reprogramming

Transcriptional regulation and post-translational modifications in the glycolytic pathway for targeted cancer therapy

SPAG4 enhances mitochondrial respiration and aerobic glycolysis in colorectal cancer cells by activating the PI3K/Akt signaling pathway

Targeting SNRNP200-induced splicing dysregulation offers an immunotherapy opportunity for glycolytic triple-negative breast cancer

Targeting LIN28B reprograms tumor glucose metabolism and acidic microenvironment to suppress cancer stemness and metastasis

Single-cell RNA-seq analysis reveals BHLHE40-driven pro-tumour neutrophils with hyperactivated glycolysis in pancreatic tumour microenvironment

Tumor Aerobic Glycolysis Confers Immune Evasion Through Modulating Sensitivity to T Cell-Mediated Bystander Killing Via TNF-α.

Targeting tumor-intrinsic SLC16A3 to enhance anti-PD-1 efficacy via tumor immune microenvironment reprogramming

Protein modifications throughout the lung cancer proteome unravel the cancer-specific regulation of glycolysis

SPI1 involvement in malignant melanoma pathogenesis by regulation of HK2 through the AKT1/mTOR pathway

Aerobic Glycolysis Promotes Tumor Immune Evasion by Hexokinase2-Mediated Phosphorylation of IκBα.

Targeting glycolysis in non-small cell lung cancer: Promises and challenges

Recent Advances in the Glycolytic Processes Linked to Tumor Metastasis